173772-63-9

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dichloro-3-aminopyridine is used as a key intermediate in the synthesis of various drugs, leveraging its ability to react with other compounds to form new substances. Its role in drug development is crucial for creating novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 2,4-Dichloro-3-aminopyridine serves as a building block for the production of pesticides. Its incorporation into these products helps in the development of effective solutions for pest control in agriculture.
Used as a Precursor for Heterocyclic Compounds:
2,4-Dichloro-3-aminopyridine is utilized as a precursor in the synthesis of a wide range of heterocyclic compounds. These compounds have diverse applications across different fields, particularly in the pharmaceutical industry for drug discovery and development.

Upstream product

• 5975-12-2 2,4-dichloro-3-nitro-pyridine 
• 1130155-48-4 (E)-4-(dimethylamino)-2-butenoic acid hydrochloride 
• 1172579-70-2 (S)-2-amino-2-(4-methyltetrahydro-2H-pyran-4-yl)-N-(4-phenyl-1,2,3-thiadiazol-5-yl)acetamide 
• 7439-89-6 iron 
• 89282-12-2 2,4-dihydroxy-3-nitropyridine 
• 626-03-9 3-deazauracil 

Downstream Products

• 91872-08-1 2,4,6-trichloro-[3]pyridylamine 
• 237435-16-4 6-bromo-2,4-dichloropyridin-3-ylamine 
• 950192-61-7 3-amino-4-chloro-2-phenylpyridine 
• 179056-98-5 3-amino-2,4-dichloro-6-methylpyridine 
• 1026076-88-9 7-chloro-5-methyl-2-phenylpyrrolo[3,2-b]pyridine 
• 237435-17-5 3-amino-4-chloro-6-methyl-2-(2-phenylethynyl)pyridine 
• 950192-63-9 C₂₄H₂₂ClN₃O₃ 
• 950192-65-1 C₂₄H₂₁N₃O₂S 
• 1422198-91-1 2-phenyl-5-(pyrrolidine-1-yl)oxazolo[5,4-b]pyridine 
• 101560-81-0 5-chloro-2-phenylthiazolo[5,4-b]pyridine 
• 1422198-81-9 5-chloro-2-phenyloxazolo[5,4-b]pyridine 

Relevant academic research and scientific papers

Heterocyclic compound as well as pharmaceutical composition, preparation method, intermediate and application thereof

The invention discloses a heterocyclic compound as well as a pharmaceutical composition, a preparation method, an intermediate and application thereof. The structure of the heterocyclic compound is shown as a formula I, and the heterocyclic compound has CDK7 inhibitory activity and can be used for treating diseases such as tumors.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C

Provided are heterocyclic compounds as inhibitors of the KRAS G12C and uses thereof. Specifically, provided are the compounds of any of formula I to XI or stereoisomers, enantiomers, atropoisomerics or pharmaceutically acceptable salts thereof. Definition of each group in the formula can be found in the specification for details.

Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway

The success of bedaquiline as an anti-tubercular agent for the treatment of multidrug-resistant tuberculosis has validated the ATP synthesis pathway and in particular ATP synthase as an attractive target. However, limitations associated with its use in the clinic and the drug-drug interactions with rifampicin have prompted research efforts towards identifying alternative ATP synthesis inhibitors with differentiated mechanisms of action. A biochemical assay was employed to screen AstraZeneca's corporate compound collection to identify the inhibitors of mycobacterial ATP synthesis. The high-throughput screening resulted in the identification of 2,4-diaminoquinazolines as inhibitors of the ATP synthesis pathway. A structure-activity relationship for the quinazolines was established and the knowledge was utilized to morph the quinazoline core into quinoline and pyrazolopyrimidine to expand the scope of chemical diversity. The morphed scaffolds exhibited a 10-fold improvement in enzyme potency and over 100-fold improvement in selectivity against inhibition of mammalian mitochondrial ATP synthesis. These novel compounds were bactericidal and demonstrated growth retardation of Mycobacterium tuberculosis in the acute mouse model of tuberculosis infection.

INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I), and G, X1, X2, R1, R2, R3, R4/sub

5-Substituted 1H-pyrrolo[3,2-b]pyridines as inhibitors of gastric acid secretion

A series of novel 1H-pyrrolo[3,2-b]pyridines was prepared relying on a copper iodide catalyzed cyclization of 2-prop-1-ynylpyridin-3-amines. A structure-activity relationship was established focusing on the influence of the substitution pattern in position 1, 3, and 5 of the heterocycle on anti-secretory activity, lipophilicity, and pKa value. Some of the compounds proved to be potent inhibitors of the gastric acid pump.

INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1 - M - U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3', R4, R4' and R5, are as described herein.

INHIBITORS OF IAP

The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I): wherein Q, X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3', R4, R4', R5, R6, R6' and n are as described herein.

Compounds and methods which modulate feeding behavior and related diseases

There are provided compounds, compositions and methods of use thereof in the modulation of feeding behavior, obesity, diabetes, cancer (tumor), inflammatory disorders, depression, stress related disorders, Alzheimer's disease and other disease conditions.

Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists

Neuropeptide Y (NPY) has been shown to play an important role in the regulation of food intake and energy balance. Pharmacological data suggests that the Y5 receptor subtype contributes to the effects of NPY on appetite, and therefore a Y5 antagonist might be a useful therapeutic agent for the treatment of obesity. In attempts to identify potential Y5 antagonists, a series of pyrrolo[3,2-d]pyrimidine derivatives was prepared and evaluated for their ability to bind to Y5 receptors in vitro. We report here the synthesis and initial structure-activity relationship investigations for this class of compounds. The target compounds were prepared by a variety of synthetic routes designed to modify both the substitution and the heterocyclic core of the pyrrolo[3,2-d]pyrimidine lead 1. In addition to identifying several potent Y5 antagonists for evaluation as potential antiobesity agents, a pharmacophore model for the human Y5 receptor is presented.